Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

n and the inclusion of DERMAGRAFT, including the fair value adjustment for DERMAGRAFT inventories in Q3 2011.

R&D

% of % of product product Q3 2011 sales Q3 2010 sales $M $M R&D (US GAAP) 201.5 20% 197.9 25% Impairment of intangible assets (16.0) - Up-front payment to Acceleron - (45.0) Depreciation (5.6) (4.4) R&D (Non GAAP) 179.9 18% 148.5 19%

Non GAAP R&D was up $31.4 million, or 21%, due to growing investment in a number of targeted R&D programs, including Sanfilippo A and other early stage development programs, in addition to increased investment in new uses for VYVANSE. Non GAAP R&D in Q3 2011 also included expenditure on the development programs acquired with Movetis and ABH, neither of which were incurred in Q3 2010.

On a US GAAP basis, R&D costs in Q3 2011 also include an intangible asset impairment charge, and Q3 2010 included the up-front payment to Acceleron.

SG&A

% of % of product product Q3 2011 sales Q3 2010 sales $M $M SG&A (US GAAP) 452.1 44% 392.4 49% Intangible asset amortization (46.4) (31.2) Impairment of intangible assets - (42.7) Depreciation (16.7) (16.1) SG&A (Non GAAP) 389.0 38% 302.4 38%

Non GAAP SG&A increased by $86.6 million, or 29% as we continue to support the growth of our existing and newly launched products. Non GAAP SG&A in Q3 2011 included expenditure for ABH and Movetis which was not incurred in the same period in 2010.

On a US GAAP basis, SG&A costs in Q3 2010 included an impairment charge to write down the DAYTRANA intangible asset to its fair value less costs to sell following agreement to divest the product to Noven Pharmaceuticals Inc. ("Noven").

Reorganization costs

For the three months to September 30, 2011 Shire recorded reorganization costs of $5.0 million (Q3 2010: $9.7 million) relating to the transfer of manufacturing from its Owings Mills facility and the establish
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industry” is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... 2014 Rancho BioSciences , the ... manually curated public data source TCGA for ... the data is now available for other oncology groups. ... and internal data sources for their Pharma, Government and ... the data that becomes more easily accessible. Rancho ...
(Date:10/30/2014)... York, NY (PRWEB) October 30, 2014 ... plan for its ICH Stability Testing and Package Test ... this investment centers on a dramatic increase in environmental ... volume of stability, storage and aging samples to be ... stage of this major capital expenditure has already taken ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
... Oct. 26, 2011 Accuray Incorporated (Nasdaq: ... announced today significant momentum in global adoption of its ... are now in use at leading cancer centers throughout ... image-guided, intensity-modulated radiation therapy (IG-IMRT) for routine radiation therapy ...
... poison from this smorgasbord of recent salmonella outbreaks in ... That,s in 2011 alone, and the list goes on, ... Prevention. But perhaps not for long, thanks to a ... of salmonella bacteria before contaminated food or animals reach ...
... ProteinSimple today announced the launch of the ... Imaging platforms. Bot1 automates analysis of protein aggregates and ... the IBC,s 11th Annual Formulation Strategy for Protein Therapeutics ... Protein therapeutic manufacturers must monitor microscopic particles and ...
Cached Biology Technology:Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 2Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 3Accuray Announces Rapid Clinical Adoption of TomoDirect™ Treatment Delivery Mode 4ProteinSimple Automates Aggregation Analysis 2
(Date:10/30/2014)... NY, October 30, 2014—Oligonucleotide-based therapeutics present unique challenges ... cause reproductive and developmental harm. New consensus guidelines ... combined chemical and biological characteristics of these novel ... , a peer-reviewed journal from Mary Ann ... free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... | Heidelberg, 30 October 2014 Biological membranes are ... understanding of adsorption of solution ions onto lipid ... Now, a new study provides a quantitative description ... solution ions. Joanna Kotyńska and Zbigniew Figaszewski from ... of a study describing these findings, just published ...
(Date:10/29/2014)... their hair as a consequence of chemotherapy will benefit ... scalp cooling technology that prevents hair loss. , The ... by global scalp cooling manufacturing company, Paxman Coolers, of ... of the University of Huddersfield. , The research will ... a background in the pharmacology of cancer treatment, which ...
Breaking Biology News(10 mins):New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... Marine Board-ESF published its 13th Position Paper, which presents ... needed to assess the effects of anthropogenic sound upon ... Board Position Paper 13 results from the activities and ... marine mammals convened at the joint European Marine Board ...
... gorgeously-decorated fish which throng Australia,s coral reefs and help earn ... be written in their genes. Of particular importance may ... re-colonise regions of reef devastated by global warming and other ... says Dr Line Bay of the ARC Centre of Excellence ...
... base and,revenues, JERICHO, N.Y., Sept. 29 ... it has executed a non-binding,Letter of Intent with ... controlling interest in Biometric Solutions, Inc. The terms ... Biometric Solutions LLC is a premiere engineering firm, ...
Cached Biology News:Effects of anthropogenic sound on marine mammals -- a research strategy 2Fishy future written in the genes 2Fishy future written in the genes 3bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 2bioMETRX, Inc. Signs Deal To Acquire Controlling Interest in Biometric Solutions, LLC 3
Pronase Reagent...
CircuLex Anti-Human S100P Polyclonal Antibody Research Focus: proliferation Storage: -20C Shipping Temperature: 4C...
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: